Results 241 to 250 of about 10,941,841 (309)

The PI3Kδ inhibitor roginolisib (IOA‐244) preserves T‐cell function and activity

open access: yesMolecular Oncology, EarlyView.
Identification of novel PI3K inhibitors with limited immune‐related adverse effects is highly sought after. We found that roginolisib and idelalisib inhibit chronic lymphocytic leukemia (CLL) cells and Treg suppressive functions to similar extents, but roginolisib affects cytotoxic T‐cell function and promotion of pro‐inflammatory T helper subsets to a
Elise Solli   +7 more
wiley   +1 more source

Contents of Issue 4, 2024 [PDF]

open access: yesZhongguo aizheng zazhi

doaj  

Contents of Issue 4, 2025 [PDF]

open access: yesZhongguo aizheng zazhi

doaj  

Erratum to 'Illustrated State-of-the-Art Capsules of the ISTH 2024 Congress' [Research and Practice in Thrombosis and Haemostasis Volume 8, Issue 4, May 2024, 102432]. [PDF]

open access: yesRes Pract Thromb Haemost
Ward C   +34 more
europepmc   +1 more source

Home - About - Disclaimer - Privacy